ERBB2 and breast cancer: In another study [51], Human Epidermal growth factor Receptor 2/neu (Her2/neu) signaling was evaluated in six Her2/neu(+) BC cell lines (LCC6Her2, MCF7Her2, SKBR3, ΒΤ474, JIMT-1, and KPL-4) that were treated with ILK inhibitor QLT0267 and resulted in a 32–87% suppression of total Her2/neu protein in these cells [51].